Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Hong

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomesH Henary, D S Hong, G S Falchook, et al.
Investigational New Drugs|June 13, 2014
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumorsD S Hong, H Henary, G S Falchook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGsA Naing, H Veasey-Rodrigues, D S Hong, et al.
ESMO Open|May 23, 2025
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancerD S Hong, R-H Xu, L Shen, et al.
The Korean Journal of Internal Medicine|June 22, 2001
A case of malignant proliferating trichilemmoma of the scalp with multiple metastasesS B Bae, K K Lee, J S Kim, et al.
Archives of Dermatological Research|April 22, 2016
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitorsG S Falchook, P Rady, J C Konopinski, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
Investigational New Drugs|May 17, 2013
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancerK H Park, J H Sohn, S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomesH Henary, D S Hong, G S Falchook, et al.
Investigational New Drugs|June 13, 2014
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumorsD S Hong, H Henary, G S Falchook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGsA Naing, H Veasey-Rodrigues, D S Hong, et al.
ESMO Open|May 23, 2025
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancerD S Hong, R-H Xu, L Shen, et al.
The Korean Journal of Internal Medicine|June 22, 2001
A case of malignant proliferating trichilemmoma of the scalp with multiple metastasesS B Bae, K K Lee, J S Kim, et al.
Archives of Dermatological Research|April 22, 2016
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitorsG S Falchook, P Rady, J C Konopinski, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
Investigational New Drugs|May 17, 2013
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancerK H Park, J H Sohn, S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Pageof 5